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Abstract
Background: The Centiloid scale has been developed to standardize measurements of amyloid PET imaging.
Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-
making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Centiloid
thresholds that maximize the agreement against core Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers
in two large independent cohorts.
Methods: A total of 516 participants of the ALFA+ Study (N = 205) and ADNI (N = 311) underwent amyloid PET
imaging ([18F]flutemetamol and [18F]florbetapir, respectively) and core AD CSF biomarker determination using
Elecsys® tests. Tracer uptake was quantified in Centiloid units (CL). Optimal Centiloid cut-offs were sought that
maximize the agreement between PET and dichotomous determinations based on CSF levels of Aβ42, tTau, pTau,
and their ratios, using pre-established reference cut-off values. To this end, a receiver operating characteristic
analysis (ROC) was conducted, and Centiloid cut-offs were calculated as those that maximized the Youden’s J Index
or the overall percentage agreement recorded.
Results: All Centiloid cut-offs fell within the range of 25–35, except for CSF Aβ42 that rendered an optimal cut-off
value of 12 CL. As expected, the agreement of tau/Aβ42 ratios was higher than that of CSF Aβ42. Centiloid cut-off
robustness was confirmed even when established in an independent cohort and against variations of CSF cut-offs.
Conclusions: A cut-off of 12 CL matches previously reported values derived against postmortem measures of AD
neuropathology. Together with these previous findings, our results flag two relevant inflection points that would
serve as boundary of different stages of amyloid pathology: one around 12 CL that marks the transition from the
absence of pathology to subtle pathology and another one around 30 CL indicating the presence of established
pathology. The derivation of robust and generalizable cut-offs for core AD biomarkers requires cohorts with
adequate representation of intermediate levels.
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Introduction
Aggregation of β-amyloid (Aβ) is a neuropathological
hallmark of Alzheimer disease (AD) and occurs decades
before the onset of clinical symptoms occur [1, 2]. Both
amyloid positron emission tomography (PET) and cere-
brospinal fluid (CSF) Aβ42 measurement are established
biomarkers of Aβ deposition that highly correlate with
post-mortem [3, 4] and brain biopsy findings [5] and serv-
ing as in vivo proxies of AD pathological findings that can
be assessed in vivo. They are included as part of the
biological definition of AD in the recent NIA-AA 2018 re-
search framework [6] for the definition of preclinical
stages of AD [7] and as well as inclusion criteria in clinical
trials [8]. CSF Aβ42 and amyloid PET show a high degree
of agreement [9–19], even though they probably measure
two different pools of amyloid. While the signal detected
by amyloid PET may reflect fibrillary amyloid [20], the de-
crease of CSF Aβ42 levels more likely reflects both fibrillar
and non-fibrillar Aβ deposits. Another difference is that
CSF Aβ42 may become abnormal before amyloid PET
[21, 22], while amyloid PET has been suggested to be
superior for grading early symptomatic AD stages [19].
For diagnostic purposes, three 18F-labelled PET radio-
tracers have been granted marketing authorizations and
are being used: [18F]flutemetamol (Vizamyl; GE Health-
care), [18F]florbetaben (Neuraceq; Life Molecular Im-
aging), and [18F]florbetapir (Amyvid, Eli Lilly). In the
clinical setting, PET scans are visually read by trained
specialists and are categorized as either positive or nega-
tive [23]. For quantitative purposes, the three different
tracers show considerable variability when measured using
the typical standardized update value ratios (SUVRs). To
improve the comparability of the retention measurements
across tracers, the Centiloid method has been proposed
[24]. This method linearly scales the measurement of a par-
ticular tracer from 0 to 100 scale, where ‘0’ represents the
average uptake in young controls and ‘100’ corresponds to
the average uptake in typical AD patients at the dementia
stage. To apply the Centiloid conversion, reference datasets,
quantification pipelines, and regions of interest and refer-
ence are available publically from http://www.gaain.org/
centiloid-project. When expressed in Centiloids (CL), opti-
mal thresholds for positivity against visual reads typically
fall within the range between 25 and 35 CL [25–27].
The applicability of CSF Aβ42 determinations with
enzyme-linked immunosorbent assays (ELISAs) has been
limited by several preanalytical and analytical factors,
resulting in lot-to-lot and between-laboratory variability.
These issues are expected to be improved by the avail-
ability of certified reference materials [28], and the problem
with analytical variation is expected to be overcome with
fully automated systems, such as the novel Elecsys® CSF
immunoassay [29]. Using this system, core AD biomarkers
in CSF have been compared to Aβ PET [22, 30, 31] and a
CSF cut-off against PET visual read has been established by
receiver operating characteristic (ROC) analysis and vali-
dated against an independent sample. The resulting areas
under the curve (AUC) of CSF Aβ42 against Aβ PET visual
read ranged from 0.85 to 0.92. Interestingly, in these stud-
ies, tau/Aβ42 ratios showed a higher agreement against
PET visual reading (AUCs 0.94–0.96) than CSF Aβ42 alone.
During the last years, investigators have started interven-
tions before the onset of clinical symptoms, when Aβ42
changes are detectable using CSF and amyloid PET bio-
markers [32–34]. Amyloid positivity is often recognized as
the earliest detectable pathophysiological abnormality in
AD. Typically, positivity has been operationalized as a
positive visual read in an amyloid PET scan. Accordingly,
quantitative cut-offs for PET imaging, but also for CSF
biomarkers, have been derived against visual reads. How-
ever, the question remains of whether lower quantitative
cut-offs can be used to detect more subtle amyloid
alterations with higher sensitivity, but which still provide
good specificity. Such cut-offs are critical for the operatio-
nalization of preventive interventions like recruiting cogni-
tively unimpaired individuals into prevention clinical trials.
Therefore, there is a need to establish sensitive, reliable and
generalizable cut-off values for amyloid PET to detect early
amyloid deposition and operationalize decision-making in
preventive intervention. In addition, visual inspection of
PET scans can render both positive and negative reads
throughout a wide range of CL values.
Initial studies to find optimal thresholds have been
performed in populations recruited from clinical popula-
tions. This translates into samples with extreme values
of both CSF Aβ42 and amyloid PET, which is AD pa-
tients with high amyloid load vs normal cognitive with
low amyloid load. This approximation results in defining
an optimal cut-off based on a population with low num-
ber of individuals with intermediate values around puta-
tive threshold values, which may hamper rendering. A
critical consideration when deriving such cut-offs is to
appropriately populate amyloid values around the
cut-offs to derive optimal and robust values. On the
other hand, as CSF Aβ42 levels start changing earlier
than the PET signal, derivation of CL cut-off values
against CSF in populations with initial amyloid abnor-
malities brings the opportunity to derive more sensitive,
yet robust and generalizable, CL values associated to
early amyloid accumulation.
In this study, we aimed at deriving optimal Centiloid
threshold values in amyloid PET that maximize the
agreement against established thresholds of CSF core
AD biomarkers. To this end, we capitalized on the
ALFA+ cohort of cognitively unimpaired individuals
enriched for risk factors for AD [35], and in order to im-
prove the generalizability of our results, analogous data
from the Alzheimer’s Disease Neuroimaging Initiative
Salvadó et al. Alzheimer's Research & Therapy           (2019) 11:27 Page 2 of 12
(ADNI; http://adni.loni.usc.edu/) was pooled with that
originated in the ALFA+ cohort.
Methods
Participants
ALFA+ is a nested longitudinal long-term study of the
ALFA (for ALzheimer’s and FAmilies) cohort [35]. In brief,
the ALFA cohort was established as a research platform to
characterize preclinical AD in 2743 cognitively preserved in-
dividuals, aged between 45 and 75 years old with increased
risk for AD. In the nested ALFA+ study, participants
undergo advanced protocols of magnetic resonance imaging
(MRI), amyloid PET imaging with [18F]flutemetamol and
CSF core AD biomarkers [35]. The first consecutive 205
participants of the ALFA+ study were included in this work.
In order to have generalizable results reflecting the
whole AD continuum, 311 participants from ADNI were
also included in this study selected according to the fol-
lowing inclusion criteria: (1) AD CSF core biomarkers
analysed with the Elecsys® tests available, (2) amyloid PET
scan acquired in less than a year from CSF collection
available, and (3) MRI acquired with a difference from the
time of the PET acquisition of less than a year. All ADNI
PET images included were acquired with [18F]florbetapir.
CSF preanalytics of ALFA+ participants
Fresh CSF samples were collected in 15-mL polypropyl-
ene tubes (Sarstedt catalog #62.554), the supernatant ali-
quoted into 0.5-mL polypropylene tubes (Sarstedt catalog
#72.730.005), and frozen within 2 h after lumbar puncture.
Aliquots were placed into long-term storage boxes and
stored at − 80 °C until shipment on dry ice for analysis.
CSF analyses on ALFA+ and ADNI
CSF samples were measured using the Elecsys® β-
amyloid(1–42) [29], and the Elecsys® phosphotau
(181P) and Elecsys® total-tau immunoassays for CSF
on a cobas e 601 analyzer (software version 05.02) at
the Clinical Neurochemistry Laboratory, University of
Gothenburg, Sweden (ALFA+) or at the Biomarker Re-
search Laboratory, University of Pennsylvania, USA
(ADNI), according to the kit manufacturer’s instruc-
tions and as described in previous studies [29].
Predefined CSF cut-offs against PET visual read
The BioFINDER and ADNI CSF AD core biomarker
cut-offs were previously determined against amyloid PET
visual read classification [22, 30]. ADNI participants were
categorized using ADNI-specific CSF thresholds (please see
Additional file 1: Table S1). Given that the ALFA+ study
shares the same preanalytical and analytical conditions as
BioFINDER, we used the same thresholds previously pub-
lished for BioFINDER to categorize ALFA+ participants
(please, see Additional file 1: Table S1).
On the other hand, we used the previously described
conversion factor from BioFINDER to ADNI values [30] in
order to pool herein the ALFA+ values with those of ADNI
(only for figures, not used for CL cut-offs derivation).
Neuroimage acquisition procedures
Each cohort had its own acquisition protocol. For ALFA+,
a T1-weighted MRI and an [18F]flutemetamol PET scan
was acquired in all participants (mean time difference 97.1
days; range [14–343]). The T1-weighted 3D-TFE sequence
was acquired in a Philips 3 T Ingenia CX scanner with a
voxel size of 0.75 × 0.75 × 0.75mm3, FOV 240 × 240 × 180
mm3, sagittal acquisition, flip angle 8°, TR = 9 .9ms, TE =
4 .6ms, TI = 900ms. PET imaging was conducted in a
Siemens Biograph mCT, following a cranial CT scan for at-
tenuation correction. Participants were injected with 185
MBq (range 166.5–203.5 Mbq) of [18F]flutemetamol, and 4
frames of 5min each were acquired 90min post-injection.
Images were reconstructed with an OSEM3D algorithm
using 8 iterations and 21 subsets and with point spread
function (PSF) and time of flight (TOF) corrections into a
matrix size of 1.02 × 1.02 × 2.03mm.
The methods for ADNI PET and MRI acquisition
methods are described in more detail elsewhere (http://
adni.loni.usc.edu/methods/documents/). In brief, all PET
images were acquired with [18F]florbetapir, which con-
sisted of 4 frames of 5 min each, acquired at 50 to 70
min post injection. Most of the T1 sequences used for
normalization were magnetization-prepared rapid ac-
quisition gradient echo (MPRAGE), acquired with
1 .5T or 3 T scanners. All images, ALFA+ and ADNI,
were visually inspected for quality control.
Image processing
All PET images were preprocessed following the Centi-
loid [24] pipeline using SPM12 (https://www.fil.ion.ucl.
ac.uk/spm/software/spm12/). In brief, PET frames were
coregistered. Averaged images were then coregistered to
corresponding MRI scans. MRIs were then segmented and
normalized to the MNI space together with PET images.
We calculated the SUVr in MNI space using the target re-
gion provided in the GAAIN website (www.gaain.org) and
the whole cerebellum as reference region. SUVr values
were then transformed to the Centiloid scale as explained
in Additional file 1: Supplementary methods.
Statistical analysis
Demographic characteristics of both cohorts were first
compared. T test for independent samples was used with
continuous variables and χ2 with dichotomous variables.
To be able to directly compare Aβ42 measures from both
cohorts, we had to transform ADNI data to account for
pre-analytical conditions [30]. This transformation was
only used to perform scatter plots but not to perform
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any other analysis, as each dataset had their own cut-offs
for the CSF biomarkers (Additional file 1: Table S1).
Optimal Centiloid cut-offs were calculated as those
that maximized the Youden’s J Index (YI) or the
overall percentage agreement (OPA; “accuracy”). YI
statistic consists of the summation of the sensitivity
and specificity [36], and the OPA reflects the per-
centage of cases with concordant binary classification
with CSF and PET. Both were calculated on the
pooled ALFA+ and ADNI data as a function of Cen-
tiloid values for Aβ42, phosphorylated tau (pTau),
total tau (tTau), and pTau/Aβ42 and tTau/Aβ42 ratios.
For each CSF biomarker as binary outcome, optimal
cut-offs were selected as those showing the maximum
value of one of the statistics after minimally smooth-
ing true-positive, true-negative, false-positive and
false-negative curves using the ‘smooth’ function in
Matlab (v2018b) with the ‘lowess’ method and a span
value of 0.1.
On top of YI and OPA, we also calculated the positive
percentage agreement (PPA, “sensitivity”) and negative
percentage agreement (NPA, “specificity”) and the area
under the curve (AUC) of the receiver operating charac-
teristic (ROC) analysis. All 95% confidence intervals
(95% CI) for all statistics were derived using bootstrap-
ping methods (n = 5000).
In order to explore the generalizability of the calcu-
lated thresholds, we also derived them in each cohort in-
dividually. Robustness of the Centiloid cut-offs were
assessed by deriving them against more liberal CSF
thresholds (higher for Aβ42 and lower for tau, Additional
file 1: Table S1). With this new CSF categorization, we
wanted to include those participants that are close to
the threshold but still classified as negative (“grey zone”,
[GZ]). To calculate these new CSF thresholds, we add
(or subtract) the 10% of the original threshold, as this
slight variation in the CSF thresholds showed helping to
reduce false negatives and to be strongly associated with
future Aβ42 positivity [37, 38].
Results
Demographic characteristics and CSF and amyloid
biomarkers
Table 1 shows demographics and characteristics of CSF
and amyloid PET biomarkers in the two cohorts included,
i.e. ALFA+ and ADNI, which have some differences. The
ALFA+ cohort has younger participants, more women
and significantly less proportion of positive participants
on all AD CSF core biomarkers, as expected as it includes
only cognitively preserved participants. By contrast, ADNI
participants are in more advanced stages of the disease,
with higher number of APOE-ε4 carriers and higher fre-
quency of positive core AD CSF biomarkers (Table 1).
This also translates into a significant difference in both
the mean and average of amyloid PET CL values between
both cohorts. As shown in Figs. 2a, 3a and 4a, the ALFA+
cohort covers intermediate CSF and CL values, whereas
ADNI participants’ CSF and CL measures show a more bi-
modal pattern. Mean and SD values for CSF biomarkers
and Centiloid measures can be found in Additional file 1:
Table S2. Scatterplots for pTau and tTau can be found in
Additional file 1: Figure S1.
Optimal CL cut-offs
We computed the optimal CL cut-off values to differen-
tiate individuals within the Alzheimer’s continuum and
controls using the AD CSF core biomarkers as a refer-
ence. We performed the analysis with CSF Aβ42 alone,
pTau/Aβ42 and tTau/Aβ42 ratios and also pTau and tTau
Table 1 Demographics and characteristics of CSF biomarkers and PET quantification measures, overall and by cohort. All the
characteristics shown in this table were statistically different (p < 0.001) between cohorts
ALL (n = 516) ALFA+ (n = 205) ADNI (n = 311)
Age, mean (SD) [range] 69.13 (9.10) [50–92] 61.01 (4.85) [50–74] 74.48 (7.07) [56–92]
Women, n (%) 286 (55.4) 134 (65.4) 152 (48.9)
Education, years mean (SD) 14.98 (3.37) 13.49 (3.58) 15.96 (2.82)
APOE-ε4 carriers, n (%) 260 (50.4) 81 (39.5) 179 (57.6)
Positive Aβ42, n (%) 273 (52.9) 60 (29.3) 213 (68.5)
Positive pTau, n (%) 323 (62.6) 56 (27.3) 267 (85.9)
Positive tTau, n (%) 294 (57.0) 50 (24.4) 244 (78.5)
Positive pTau/Aβ42, n (%) 258 (50.0) 24 (11.7) 234 (75.2)
Positive tTau/Aβ42, n (%) 246 (47.7) 21 (10.2) 225 (72.3)
Diagnostic, n (%) CN/MCI/AD 256 / 237 / 23 (49.6)/(45.9)/(4.5) 205 / 0 / 0 (100)/(0)/(0) 36 / 237 / 23 (11.6)/(76.2)/(7.4)
Time difference CSF-PET, days mean (SD) [range] 45.2 (60.3) [0–343] 97.1 (65.1) [14–343] 11.0 (17.2) [0–126]
Aβ β-amyloid, AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE Apoliprotein E, CN cognitively normal, MCI mild cognitive impaired
participants, pTau phosphorylated tau, SD standard deviation, tTau total tau
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alone. We studied the pooled data from ALFA+ and
ADNI cohorts, using cohort-specific CSF thresholds.
Table 2 summarizes the optimal CL values, using the
pooled data from ALFA+ and ADNI cohorts, and associ-
ated statistical performance against CSF Aβ42, pTau/Aβ42,
tTau/Aβ42, pTau and tTau. Figure 1 shows the associated
ROC curves.
CSF Aβ42
Derivation of Centiloid cut-off against Aβ42 is shown in
Fig. 2. The resulting cut-offs with this analysis were 12.1
CL with YI’s optimization and 11.6 CL OPA’s optimiza-
tions, which corresponded with maximum values YI of
0.66 (95% CI 0.59–0.72) and OPA of 0.83 (95% CI 0.81–
0.86), respectively. The corresponding area under the curve
for CSF Aβ42 was of 0.87 (95% CI 0.84–0.90). PPA and
NPA values for these CL cut-offs are shown in Table 2.
The optimal cut-offs calculated against 10% variation of
the CSF threshold were similar (CL = 11.1 CL with OPA,
0.85, and CL = 12.9 with YI, 0.70; Additional file 1: Table S3
and Figure S2), and the AUC was slightly improved AUC=
0.90. When CL cut-offs were derived separately in the two
independent cohorts, the AUC for CSF Aβ42 was higher in
the ADNI cohort than in ALFA+ (0.85 vs 0.76 Add-
itional file 1: Table S4). The optimal threshold for the
ALFA+ cohort were slightly lower to the one found in
the pooled analysis (CL = 5.4 with YI and CL = 10.7 with
OPA, Additional file 1: Table S4 and Figure S3), whereas,
for ADNI, the optimal cut-off resulted was significantly
higher (CL = 36.2 CL with YI and CL = 33.1 with OPA,
Additional file 1: Table S4 and Figure S4).
CSF tau/Aβ42 ratios and tau
Very similar results were found in both tau over Aβ42 ra-
tios (Figs. 3 and 4). The optimal cut-off derived with both
cohorts merged for pTau/Aβ42 was 28.8 CL with an AUC
of 0.97 [0.96–0.99] with both YI and OPA’s maximization
and for tTau/Aβ42 29.7CL with YI’s maximization and
30.1 CL with OPA’s maximization with an AUC of
0.96 [0.94–0.97] (Table 2).
Unlike for CSF Aβ42, optimal thresholds against varia-
tions of the CSF cut-offs resulted in a reduced optimal
threshold of CL = 21.4 for both tau ratios with YI’s
maximization and CL = 20.6 for both tau ratios with OPA’s
maximization (Additional file 1: Table S3 and Figure S2).
When derived in both cohorts separately, thresholds were
again slightly lower in the ALFA+ cohort (CL = 20.0 and
CL = 24.8 for pTau ratio and CL = 20.1 and CL = 24.9 for
tTau ratio; Additional file 1: Figure S3 and Table S4) and
significantly higher for ADNI (CL = 34.4 and CL = 31.5 for
pTau ratio and CL = 34.7 and CL = 32.5 for tTau ratio;
Additional file 1: Figure S4 and Table S4).
Optimal cut-offs for CSF pTau and tTau were similar
to those for the ratios, but with lower AUCs (Table 2).
Meanwhile, tTau cut-offs remained relatively stable when
using YI or OPA as criterion (CL = 28.6 and CL = 28.8, re-
spectively); pTau cut-offs changed highly (29.3 CL with YI
vs 18.7 with OPA; Additional file 1: Table S3). The analysis
against 10% CSF variations resulted in similar cut-offs
with similar AUCs except for tTau cut-off resulting from
OPA’s maximization that lowered up to 15.9 CL (Add-
itional file 1: Table S3 and Figure S2). Finally, the behav-
iour of the cut-offs in the two cohorts separately was quite
different with respect to tau over Aβ42 ratios and resulted
in lower AUCs than the optimal cut-off (Additional file 1:
Figure S2, S3 and, Table S4).
Discussion
In this paper, we sought to calculate the optimal Centi-
loid cut-off values from amyloid PET data to maximize
the agreement against previously established thresholds
for positivity on core AD CSF biomarkers. At a first
glance, this might be regarded as a circular exercise,
since these CSF cut-offs were originally derived to max-
imally concord with positive visual reading of PET scans.
Under this rationale, all resulting Centiloid cut-offs
would have be expected to fall in the range that opti-
mally discriminates negative from positive visual reads,
which is between 25 and 35 CL [25, 26]. On the con-
trary, optimal agreement for CSF Aβ42 was observed for
a cut-off of 12 CL. This seemingly unexpected result can
be explained by the clearly non-linear relationship be-
tween amyloid PET Centiloids and CSF Aβ42, as previ-
ously reported [39]. Almost all subjects with CSF Aβ42
over 1000 pg/ml showed Centiloid values below 20, and
only for CSF values < 1000 pg/ml, a linear association
could be intuited. This nonlinear association makes
goodness criteria (both the Youden’s Index and the over-
all percentage agreement) to plateau between 10 and 40
CL (Fig. 2). Under these circumstances, to derive stable
optimal cut-offs, it is critical to make use of a test sample
comprising both sufficient concordant positive and nega-
tive cases as well as a good representation of individuals
falling within intermediate amyloid ranges (10 < CL < 40
and 500 < CSF Aβ42 < 1000 pg/ml). In this study, this was
achieved by pooling the ADNI and ALFA+ datasets.
The independent derivation of optimal CSF Aβ42
cut-offs in the two cohorts confirmed this rationale. In
the ADNI sample, optimal values fell in the expected
range of visual reads (between 33 and 36 CL) whereas
the optimal threshold in the ALFA+ sample is closer to
that in the pooled sample (between 5 and 11 CL). This
result confirms that the derivation of optimal cut-offs is
very sensitive to the recruitment strategy of the refer-
ence sample, with clinical ones rendering higher cut-offs
than population based ones with a better representation
around the range of values where cut-offs are expected
to lay. Previous literature has suggested that CSF Aβ42
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values become positive before amyloid PET [21, 22].
This may be related to amyloid PET visual read and
SUVRs cut-offs on clinical populations. In these popula-
tions, the visual read is performed in patients with either
prodromal AD or dementia due to AD; hence, the amyl-
oid load is supposed to have reached its ceiling. By con-
trast, the ALFA+ population reflects a cohort of early
amyloid accumulators at risk for cognitive impairment;
therefore, a positive visual read may be reached when
amyloid is still not at its peak. Indeed, the threshold of
12 CL is robust against variations in the cut-off for CSF
positivity (Additional file 1: Table S3) as well as if only
the ALFA+ dataset is used for its derivation.
Although 12 CL may initially be regarded as a low
value for amyloid positivity, it matches recent reports of
Centiloid cut-offs against postmortem measures of AD
neuropathology showing that 12.2 CL optimally detected
Consortium to Establish a Registry for Alzheimer’s Dis-
ease (CERAD) moderate-to-frequent neuritic plaques,
whereas 24.4 CL identified intermediate-to-high AD
neuropathologic change (ADNC) differences [40]. An-
other similar study showed that a threshold < 10 CL was
optimal for ruling out the presence of amyloid plaques,
whereas CL > 20 suggests significant amyloid pathology
[26]. However, we would like to point out that we did
not want to affirm that the CL cut-offs found show
amyloid pathology, but only to find those CL values that
maximally agree with those of the CSF core AD bio-
markers. The fact that the CL cut-offs derived in this
study agree with a previous one done with neuropatho-
logical data is only a marker that these values might
have an actual biological meaning, more than only a
practical one. But this hypothesis should be tested in an-
other work, preferably with longitudinal data.
Unlike CSF Aβ42, for tau/CSF Aβ42 ratios, the opti-
mal CL cut-offs fell within the expected range (28–30
CL) given the linear relationship between this bio-
marker and amyloid PET Centiloids. Indeed, tau/CSF
Aβ42 ratios showed higher AUC versus amyloid PET
Centiloids than CSF Aβ42, in agreement with the previous
reports [22, 27, 30, 31]. The higher capacity of tau/CSF
Aβ42 ratios to predict Centiloids may be accounted for by
two different factors. On the one hand, CSF ratios may
provide a more stable measurement than absolute values
since they provide an inherent normalization against pro-
tein production and release to the CSF, between-individual
variations in CSF dynamics, and pre-analytical conditions.
Therefore, the lower variability in the CSF ratios may ac-
count for better AUCs. On the other hand, CSF Aβ42 has
been proposed to become abnormal prior to amyloid PET
[21, 41]. This fact might stem from the fact that both tech-
niques probe different pools of the amyloid protein. There-
fore, the combination of measurements of Aβ with those
of tau, a pathological change that is expected to occur later
in the AD continuum [41], might show better agreement
with amyloid PET, which is also expected to become ab-
normal later than CSF Aβ42.
Together with previous studies, the observed thresh-
olds might be useful to flag two different inflection
points in preclinical AD stages. A cut-off below 12 CL
might be optimal to rule out-amyloid pathology, whereas
a cut-off over 29 CL might be denoting established
Fig. 1 Summary of ROC curves for Centiloid cut-off derivation against CSF biomarkers. pTau, phosphorylated tau; tTau, total tau; CSF,
cerebrospinal fluid; ROC, receiver operating characteristic
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pathology. These kinds of thresholds have typically been
used to dichotomize continuous values into two categories
for clarity and ease of use. However, alternatives have also
been considered and include the score of the severity of
each biomarker on a semi-continuous scale as considered,
for instance, in the A/T/N scheme [42]. Therefore, an op-
tion would be to categorize the full range of variation of
biomarker values in three categories: one that excludes
any pathology, another intermediate category that would
indicate early and developing pathology and a third one
that corresponds with established pathology.
Two goodness criteria have been used here to derive
optimal cut-offs: the Youden’s Index, which balances
sensitivity and specificity, and the overall percentage
agreement, which is sensitive to the percentages of posi-
tives versus negatives in the test sample. Both rendered
very similar values and the Centiloid cut-offs proposed
here are robust against variations in the threshold values
for CSF positivity. Still, the Youden’s index showed a
more noisy behaviour than the overall percentage agree-
ment, particularly in the analysis of the two individual
samples. In order to obtain more robust estimates of
Fig. 2 Derivation of amyloid PET Centiloid cut-offs using Aβ42 CSF biomarker. Upper row shows a scatterplot of PET quantitative measures in
Centiloids against CSF Aβ42 biomarker values for both ALFA+ (blue) and ADNI (red) participants. Vertical lines depict previously published CSF
threshold (Aβ42 1098 pg/ml [22, 30]), and horizontal lines depict optimal cut-offs derived in this study (YI derived: green, OPA derived: yellow).
Two outliers were excluded of this picture for having CL value higher than 200. Second row shows this cut-offs derivation by the maximization of
YI (left) and OPA (right). The YI (green) was calculated from PPA (blue) and NPA (red) values. The OPA (green) was calculated from PPV (blue) and
NPV (red) values. Derivation was done with participants of both cohorts merged. Aβ, amyloid; CSF, cerebrospinal fluid; YI, Youden’s J index; PPA,
positive percentage agreement; NPA, negative percentage agreement; CL, Centiloids
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classification performance, more subjects across the
full AD continuum would be needed. This is a rele-
vant effect because in previous similar works, the
Youden’s Index has been typically selected as the
reference measurement of agreement [22, 30, 31].
Hansson et al. [30] added reliability measures to per-
formance metrics to derive optimal cut-offs. We
handled the noisy behaviour of performance metrics
by deriving optimal cut-offs after some minimal
smoothing of the data. This approach proved to be
efficacious to derive stable cut-offs even in the ana-
lysis of the individual cohorts.
Irrespective of the approach to counter the effect of
noisy agreement estimates, additional analysis with lar-
ger samples might be needed to yield more robust and
generalizable cut-offs. To this end, future work will focus
on pooling additional samples. In addition to a limited
sample size, we rely on the comparability of PET and
CSF measures across the two studied samples. While
agreement on CSF data is certainly improved with the
Elecsys® tests and with the use of the Centiloid method
on PET scans, we cannot rule out the presence of a cer-
tain degree of sample-dependent bias in the data ana-
lysed. Still, when computing the cut-offs solely using the
Fig. 3 Derivation of amyloid PET Centiloid cut-offs for CSF pTau/Aβ42. Top row shows scatterplots of PET quantitative measures in
Centiloids against CSF pTau/Aβ42 biomarker values for both ALFA+ (blue) and ADNI (red) participants. Vertical line depicts previously
published CSF thresholds (pTau/Aβ42 0.022 [22, 30]), and horizontal line depicts optimal cut-offs derived in this study (YI and OPA derived
cut-offs are equal). Two outliers were excluded of this picture for having CL value higher than 200. Second row shows this cut-off
derivation by maximization of YI (left) and OPA (right). The YI (green) was calculated from PPA (blue) and NPA (red) values. The OPA
(green) was calculated from PPV (blue) and NPV (red) values. Derivation was done with participants of both cohorts merged. pTau,
phosphorylated tau; CSF, cerebrospinal fluid; YI, Youden’s J index; PPA, positive percentage agreement; NPA, negative percentage
agreement; CL, Centiloids
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ALFA+ cohort results were very similar, thus sug-
gesting that any remaining bias is small and did not
have a significant impact on our results. Another
limitation may stem from the somewhat limited sam-
ple analysed here may not be sufficient to derive ro-
bust generalizable cut-off values. Additional analysis
with bigger sample sizes and more amyloid PET
tracers that the two used here may overcome this
limitation.
In summary, we have derived optimal Centiloid values
to maximize the agreement against core AD CSF bio-
markers. Regarding Aβ, a relatively low value of 12 CL
optimally corresponded to CSF Aβ42 positivity, in line
with Centiloid thresholds derived against post-mortem
measures of AD neuropathology. On the other hand,
CSF tau/Aβ42 ratios were better predicted by a higher
Centiloid cut-off of 29 CL, which is in line with those
optimally discriminating positive from negative visual
reads on PET scans. In agreement with previous reports,
CSF tau/Aβ42 ratios showed a higher capacity to predict
amyloid PET Centiloids than CSF Aβ42. Overall, our re-
sults provide reference values in the Centiloid scale and
suggest two relevant inflection points the development
of early AD pathology across the full AD continuum.
Fig. 4 Derivation of amyloid PET Centiloid cut-offs for CSF tTau/Aβ42. Top row shows scatterplots of PET quantitative measures in Centiloids
against CSF tTau/Aβ42 biomarker values for both ALFA+ (blue) and ADNI (red) participants. Vertical line depicts previously published CSF
thresholds (tTau/Aβ42 0.26 [22, 30]), and horizontal lines depict optimal cut-offs derived in this study (YI derived: green, OPA derived: yellow). Two
outliers were excluded of this picture for having CL value higher than 200. Second row shows this cut-off derivation by maximization of YI (left)
and OPA (right). The YI (green) was calculated from PPA (blue) and NPA (red) values. The OPA (green) was calculated from PPV (blue) and NPV
(red) values. Derivation was done with participants of both cohorts merged. tTau, total tau; CSF, cerebrospinal fluid; YI, Youden’s J index; PPA,
positive percentage agreement; NPA, negative percentage agreement; CL, Centiloids
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